Key result
Tirzepatide cuts hsCRP by ~34% and lowers NT-proBNP across pooled trials.
Why the study?
The effects of tirzepatide on cardiorenal biomarkers and functional capacity in heart failure have not been comprehensively synthesized.
Does tirzepatide reduce cardiorenal biomarkers and improve functional capacity compared to placebo or standard of care in patients with heart failure?
Meta-Analysis (n=5,406)
Does tirzepatide reduce cardiorenal biomarkers and improve functional capacity compared to placebo or standard of care in patients with heart failure?
Effect estimate: 34.3% reduction (95% CI -38.4% to -30.1%)
p-value: p=<.0001
Tirzepatide produces consistent reductions in inflammatory and natriuretic biomarkers in patients with heart failure, with early signals suggesting functional and renal benefits that require further dedicated trial confirmation.
Tirzepatide reduces hsCRP and NT-proBNP in HF; extends SUMMIT data and supports dedicated outcome trials.
Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated clinical benefits in heart failure with preserved ejection fraction (HFpEF) and obesity. However, its effects on cardiorenal biomarkers and functional capacity have not been comprehensively synthesized. We hypothesized that tirzepatide produces significant reductions in cardiorenal biomarkers and improvements in functional capacity compared to placebo or standard of care. Methods This systematic review and meta-analysis (PROSPERO: CRD42026137255) searched PubMed, Embase, CENTRAL, Web of Science, and Scopus from inception to April 17, 2026, without restrictions. Randomized controlled trials and prospective observational studies reporting NT-proBNP, high-sensitivity C-reactive protein (hsCRP), Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), 6-minute walk test (6 MWT), or renal outcomes with tirzepatide vs placebo or standard of care were included. Data were pooled using random-effects models with Hartung–Knapp–Sidik–Jonkman adjustment. Results Seven studies (5 RCTs, 2 observational; 5406 participants) were included. Tirzepatide significantly reduced hsCRP by 34.3% (95% CI: −38.4% to −30.1%; P < .0001; I2 = 0.0%; 6 studies) and NT-proBNP by 17.6% (95% CI: −26.7% to −8.5%; P = .0001; I2 = 58.1%; 3 studies). In the SUMMIT trial, KCCQ-CSS improved by 5.1 points (P < .001) and 6 MWT by 15.8 m (P = .004). Single-trial data demonstrated estimated glomerular filtration rate (eGFR) preservation (+2.90 mL/min/1.73 m2/year; 95% CI: 0.94 to 4.86) and urine albumin-to-creatinine ratio reduction (−25.0%; 95% CI: −36.0% to −13.0%). Conclusion Tirzepatide produces consistent anti-inflammatory effects and significant natriuretic peptide reductions, supported by moderate Grading of Recommendations Assessment, Development and Evaluation certainty. Evidence for functional and renal outcomes remains limited to single-trial analyses and should be considered hypothesis-generating pending larger dedicated heart failure trials.
No takes yet. Share an insight, caveat, or question.
Eisa et al. (2026) conducted a meta-analysis in heart failure with preserved ejection fraction and obesity (n=5,406). Tirzepatide vs. placebo or standard of care was evaluated on high-sensitivity C-reactive protein (hsCRP) reduction (34.3% reduction, 95% CI -38.4% to -30.1%, p=<.0001). Tirzepatide significantly reduced hsCRP by 34.3% (95% CI: -38.4% to -30.1%; P<.0001) and NT-proBNP by 17.6% across pooled trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: